Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › Chris Mason: Starmer's defence plan leaves crunching...
Business & Finance

Chris Mason: Starmer's defence plan leaves crunching trade‑offs for Burnham to confront

Chris Mason: Starmer's defence plan leaves crunching trade‑offs for Burnham to confront
BBC Politics Wednesday 01 July 2026, 07:18 UTC 1 min read
Key Points

The BBC's political editor Chris Mason reflects on the fallout from the Defence Investment Plan.

The BBC's political editor Chris Mason reflects on the fallout from the Defence Investment Plan.
Chris Mason (PERSON) Starmer (PERSON) Burnham (PERSON) the Defence Investment Plan (ORG)
Originally published by BBC Politics Read original →

Related Stories

Germany news: Ruling due on Austria border checks

Germany news: Ruling due on Austria border checks Published July 1, 2026last updated July 1, 2026What you need to know - A court in Munich is examining whether personal border checks between Germany and Austria are lawful. - The case was brought by a commuter who regularly travels by train from Munich to Innsbruck - Germany's ruling coalition leaders are meeting today at the chancellery ahead of the summer break. Chancellor Friedrich Merz is hosting the coalition committee, with a "major...

Deutsche Welle 24m ago

Starmer to take PMQs as he faces backlash over ‘poisoned chalice’ defence investment plan – UK politics live

Concerns that plan is not properly funded and will take cash from much-needed road projectsGood morning. Yesterday Keir Starmer published the defence investment plan (Dip), which was probably the last substantial announcement of his premiership. Today he is facing what will probably be his second last PMQs (he is expected to be at the Nato summit next Wednesday, and he’ll have his swansong on 15 July), and the session is likely to be dominated by complaints about the Dip.

The Guardian World 27m ago

Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess

Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox treatment Relfydess. The US regulator made observations in a complete response letter following a pre-license inspection and Galderma is putting in place corrective and preventive actions, the company said in a statement Wednesday. The stock fell as much as 6.6%,...

Bloomberg Markets 30m ago

Eni, Mercuria to Form Global Energy Commodities Trading Venture

Commodities Eni, Mercuria to Form Global Energy Commodities Trading Venture Italian oil company Eni SpA and commodities merchant Mercuria Energy Group Ltd. signed a deal to trade energy together globally. The two firms agreed to form an equally owned venture to trade energy commodities “through a holding structure with international trading hubs,” Eni said in a statement on its website.

Bloomberg Markets 34m ago